ERBB2 and neoplasm: A recent comparison of 119 breast cancers stained by the Dako polyclonal HercepTest and the Ventana monoclonal 4B5 assay revealed that the former classified more cases as HER2 2+ [22], including tumours with HER2 amplification and tumours that were non-amplified (HER2-low).